Agpat2 Polyclonal Antibody, PE Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-5032R-PE |
| Product Name | Agpat2 Polyclonal Antibody, PE Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Pig, Horse |
| Specifications | |
| Conjugation | PE |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human Agpat2 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 10555 |
| Subcellular location | Cell membrane |
| Synonyms | LPAAB; BSCL; BSCL1; EC 2.3.1.51; LPAAB; LPAAT beta; Lysophosphatidic acid acyltransferase beta; 1 acyl sn glycerol 3 phosphate acyltransferase beta; 1 acylglycerol 3 phosphate O acyltransferase 2; 1 AGP acyltransferase 2; 1 AGPAT2 antibody Berardinelli Seip congenital lipodystrophy.PLCB_HUMAN |
| Background | Agpat2 is a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. It is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in its have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. |
| Application Dilution | |
| IF(IHC-P) | |
| IF(IHC-F) | |
| IF(ICC) | |